



Supplementary Figures


LOR to anti-TNF is associated with low/undetectable serum drug concentration in 50-70% of cases




In CD/UC, LOR has been associated with low/undetectable serum drug concentrations



Accelerated drug clearance can be caused by an immunogenic reaction with formation of ADA




Accelerated drug clearance can be caused by non-immune mediated mechanisms




Supplementary Figure 1: Results after the first round of vote in the Delphi-style process for relevance of adequate anti-TNF drug concentrations. Each of the eight specialists ranked the statements by agreement from rank 1 (strong disagreement) to rank 4 (strong agreement). Y-axis shows number of specialists choosing each rank. ADA, anti-drug-antibodies; LOR, loss of response


Severity and extent of IBD




Male sex







BMI








Concomitant IM use









Supplementary Figure 2: Results after the first round of vote in the Delphi-style process for identification of factors affecting non-immune-mediated drug clearance. Each of the eight specialists ranked these factors by agreement from rank 1 (strong disagreement) to rank 4 (strong agreement). Y-axis shows number of specialists choosing each rank. BMI, body mass index; IM, immunomodulators

IFX 3-7ug/mL**ADA 8-12ug/mL****CZP 8-12ug/mL****Golimumab min threshold 2.5ug/mL**

Supplementary Figure 3: Results after the first round of vote in the Delphi-style process for definition of optimal anti-TNF drug trough levels to achieve mucosal healing. Each of the eight specialists ranked the threshold values by agreement from rank 1 (strong disagreement) to rank 4 (strong agreement). Y-axis shows number of specialists choosing each rank. ADA, adalimumab; CZP, certolizumab; IFX, infliximab

Adverse events**Loss of response****Mucosal healing****CRP levels****Calprotectin levels**

Supplementary Figure 4: Results after the first round of vote in the Delphi-style process for identification of outcomes that anti-drug-antibodies are predictive for. Each of the eight specialists ranked these outcomes by agreement from rank 1 (strong disagreement) to rank 4 (strong agreement). Y-axis shows number of specialists choosing each rank.



Supplementary Figure 5: Results after the first round of vote in the Delphi-style process for identification of key parameters required for clinical decision making in case of LOR to anti-TNF. Each of the eight specialists ranked these parameters by agreement from rank 1 (strong disagreement) to rank 4 (strong agreement). Y-axis shows number of specialists choosing each rank.